[ad_1]
Eli Lilly reported that his drug Trulicity (dulaglutide) reduced major cardiovascular (CV) events (CV) by 12% in the REWIND trial of patients with type 2 diabetes.
MACE was measured as a composite endpoint of nonfatal myocardial infarction (heart attack), nonfatal stroke or CV death.
A constant MACE 3 effect was observed in subjects with and without established cardiovascular disease. The CV risk reduction was maintained throughout the study.
Trulicity is a weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA) intended to improve blood glucose levels in adults with type 2 diabetes, when it is used in addition to a diet and diet. l & # 39; exercise.
The multi-center, randomized, double-blind, placebo-controlled REWIND trial was conducted to compare 1.5 mg Trulicity with placebo, in combination with standard therapy, in 9,901 subjects in 24 countries.
All participants in the study had CV risk factors, but only 31% of them had established cardiovascular disease. The main result of the CV study was the first occurrence of MACE.
The data showed that the three components of the CV result contributed to the significant decrease provided in MACE 3 with Trulicity.
Therapy has also led to a reduction in composite microvascular outcomes, with fewer composite renal outcomes. Additional badyzes revealed a reduction in the progression of kidney disease in patients treated with Lilly's drug.
In addition, it has been shown that the drug decreased HbA1c level during the test compared to a median value of 7.2% compared to placebo.
The safety profile of the drug was consistent with that of the GLP-1 receptor agonist clbad, with the most common adverse events resulting in discontinuation being gastrointestinal.
Brad Woodward, global development manager for Lilly Incretins, said, "The detailed results of our historic REWIND trial demonstrate cardiovascular benefit in a more representative population of people with type 2 diabetes.
"These data suggest that Trulicity can help doctors and people with type 2 diabetes better manage blood glucose and cardiovascular risks over the long term."
The company has submitted the study data for review by US and European regulatory authorities.
Source link
